For more than four decades, High-Performance Computing (HPC) has been the backbone of scientific discovery. Its primary role was straightforward: run large-scale, physics-based simulations such as molecular dynamics, computational chemistry, seismic imaging, weather forecasting and computational fluid dynamics.
That model is now undergoing a profound transformation.
According to Hyperion Research, AI is being used at more than 78% of HPC sites worldwide. In comparison, the combined HPC and AI market grew by 23.5% in 2024, reaching approximately $60 billion and projected to approach $140 billion by 2030.
AI is no longer simply another workload running beside HPC. It is increasingly becoming an integral part of scientific computing itself.
Nowhere is this convergence more significant than in life sciences and healthcare (LSH), where organizations face growing pressure to accelerate research timelines, improve outcomes and maximize the value of existing technology investments.
Why Life Sciences is at the center of the HPC-AI convergence
Life Sciences organizations have long relied on HPC to support computationally intensive workloads such as:
- Molecular dynamics simulations
- Computational chemistry
- Molecular docking
- Genomic analysis
- Cryo-electron microscopy
- Medical-image reconstruction
- Epidemiological modelling
- Clinical and translational research
While HPC has enabled breakthrough discoveries, traditional approaches often require extensive computational effort, long processing times and multiple rounds of experimentation.
AI is changing that equation.
Rather than replacing HPC, AI is augmenting it. Machine learning models can interpret complex datasets, prioritize simulations, predict likely outcomes and guide scientists toward the most promising experiments. Traditional simulations continue to provide scientific validation, while AI helps determine where to invest time and resources.
The result is a new research paradigm in which prediction, simulation and validation operate as a unified workflow.
Transforming genomics through AI-driven discovery
Genomics is one of the clearest examples of this transformation.
GPU-accelerated solutions such as NVIDIA Parabricks and AI-powered variant-calling tools like Google DeepVariant have dramatically reduced whole-genome analysis times. Tasks that previously took more than a day on CPU-based systems can now be completed in well under an hour.
At the same time, transformer-based genomic foundation models are creating entirely new possibilities for analyzing genetic data at scale, enabling researchers to uncover patterns and relationships that were previously difficult to identify.
The commercial momentum reflects the technological shift. The AI-in-genomics market is projected to grow from $1.56 billion in 2026 to $12.57 billion by 2034, representing nearly 30% compound annual growth.
For healthcare providers, pharmaceutical companies and research institutions, this translates directly into faster insights, improved precision medicine initiatives and more efficient genomic research programs.
Reinventing drug discovery
Drug discovery is experiencing an even more dramatic transformation.
Historically, researchers relied on extensive computational screening and simulation to identify promising compounds. While effective, this approach can be costly, time-consuming and resource-intensive.
AI is changing the front end of the discovery process.
Modern AI models can:
- Generate novel molecular structures
- Predict protein structures
- Estimate molecular properties
- Prioritize candidate compounds
- Identify promising biological targets
Traditional HPC workloads then provide the scientific rigor needed for validation through molecular dynamics, quantum chemistry simulations and free-energy calculations.
This creates a powerful combination in which AI expands the search space while HPC provides scientific confidence.
As a result, organizations can evaluate a larger number of potential therapies while focusing expensive simulation and laboratory resources on the most promising candidates. The AI-in-drug-discovery market is expected to grow from $5.09 billion in 2026 to $17.56 billion by 2031, reflecting a CAGR of 28.1%.
As AI adoption expands, organizations must rethink their infrastructure strategy.
The challenge is not simply adding GPUs to existing clusters. It requires modernization across compute, storage, networking, software platforms and operational processes.
Re-engineering the Life Sciences HPC stack
Building an AI-ready research platform requires changes across the technology landscape:
- Compute architecture: Retain CPU and large-memory nodes for genomics and traditional simulation workloads while adding GPU resources for AI training, inference and accelerated scientific applications
- Storage and I/O: Combine parallel file systems with high-performance flash and object storage to support simulation checkpoints, genomic datasets, AI pipelines and mixed workload requirements
- Network and interconnect: Increase bandwidth and reduce latency between compute, storage and accelerator resources to enable distributed AI training and tightly coupled scientific computing
- Scheduling and software: Extend traditional Slurm-based environments with containers, Kubernetes, workflow automation and MLOps capabilities that support AI development and production deployment
- Security and compliance: Maintain separation between research, clinical and regulated environments while strengthening governance, model traceability, auditability and data privacy controls
- Monitoring and operations: Track infrastructure utilization, GPU efficiency, inference performance, energy consumption, storage bottlenecks and overall scientific productivity
- Power and cooling: Assess facility readiness for high-density accelerator infrastructure and introduce liquid-cooling technologies where traditional air-cooled environments are insufficient.
The objective is not to create a separate AI environment operating alongside a legacy HPC platform.
The objective is to build a single, converged HPC-AI platform where simulation, model training, inference and scientific workflows share the same infrastructure, datasets and operational controls.
Accelerating the journey with HCLTech’s HPC-to-AI upgrade services
Moving from a traditional HPC environment to a converged HPC-AI platform requires more than just adding GPU infrastructure. Organizations must align compute, storage, networking, software platforms and operational processes to support a new generation of AI-enabled scientific workflows while maintaining the reliability of existing research environments.
A successful transformation typically begins with understanding current workload requirements, validating new AI use cases and modernizing infrastructure in a phased manner. The goal is to create a unified platform where simulation, AI training, inference and data-driven research can operate seamlessly together.
HCLTech helps life sciences organizations navigate this transition by combining expertise in HPC infrastructure, AI Engineering, life sciences research workflows and managed operations. Through a structured modernization approach, organizations can accelerate adoption, reduce transformation risk and maximize the value of existing technology investments.
The HCLTech advantage
Successful HPC-to-AI transformation requires expertise across infrastructure, software, operations and scientific research.
HCLTech brings together four critical capabilities:
- End-to-end ownership: Assessment, architecture, deployment, migration, operations and optimization
- HPC and AI Engineering expertise: Integration of simulation, analytics, AI training and production inference
- Life sciences domain understanding: Alignment with genomics, drug discovery and regulated research requirements
- Flexible consumption models: Support for on-prem, hybrid-cloud and HPC-as-a-Service environments
The future is a converged HPC-AI platform.
The future of life sciences computing is not AI or HPC. It is AI and HPC working together as a unified platform.
Simulation continues to provide scientific truth. AI expands the discovery space. Automated workflows connect data, models, researchers and laboratories into a seamless innovation engine.
For life sciences organizations, this convergence offers a powerful opportunity to accelerate genomic insights, evaluate more drug candidates, shorten research timelines and maximize the value of existing technology investments.
The organizations that successfully combine predictive intelligence with scientific simulation will define the next era of scientific discovery. HCLTech helps make that transformation practical through a structured journey from traditional HPC environments to enterprise-scale AI-enabled research platforms.
References
